Baloni, Priyanka
Arnold, Matthias http://orcid.org/0000-0002-4666-0923
Buitrago, Luna
Nho, Kwangsik
Moreno, Herman
Huynh, Kevin
Brauner, Barbara
Louie, Gregory
Kueider-Paisley, Alexandra
Suhre, Karsten http://orcid.org/0000-0001-9638-3912
Saykin, Andrew J. http://orcid.org/0000-0002-1376-8532
Ekroos, Kim
Meikle, Peter J. http://orcid.org/0000-0002-2593-4665
Hood, Leroy
Price, Nathan D.
Arnold, Matthias
Blach, Colette
Kaddurah-Daouk, Rima
Doraiswamy, Murali
Mahmoudiandehkordi, Siamak
Welsh-Bohmer, Kathleen
Plassman, Brenda
Krumsiek, Jan
Batra, Richa
Saykin, Andrew
Yan, Jingwen
Risacher, Shannon L.
Meikle, Peter
Wang, Tingting
Ikram, Arfan
Ahmad, Shahzad
Hankemeier, Thomas
Hernandez, Ivan A.
Heinken, Almut
Martinelli, Filippo
Thiele, Ines
Hertel, Johannes
Hensen, Tim
Hulshof, Tim
Farrer, Lindsay A.
Au, Rhoda
Qiu, Wendy Wei Qiao
Stein, Thor
Karu, Naama
Borkowski, Kamil
Newman, John
Jia, Wei
Xie, Guoxiang
Wang, Jingye
Wei, Runmin
Rader, Dan
Kling, Mitchel
Shaw, Leslie
Doraiswamy, P. Murali
Funk, Cory C. http://orcid.org/0000-0002-5229-9011
Hernández, A. Iván
Kastenmüller, Gabi http://orcid.org/0000-0002-2368-7322
Baillie, Rebecca http://orcid.org/0000-0003-3966-6320
Han, Xianlin http://orcid.org/0000-0002-8615-2413
Kaddurah-Daouk, Rima http://orcid.org/0000-0003-1858-5732
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AG058942, AG057452, AG069901)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 20 January 2022
Accepted: 20 September 2022
First Online: 8 October 2022
Competing interests
: The authors declare the following competing interests: R.K.D. is an inventor of key patents in the field of Metabolomics and holds equity in Metabolon, a biotech company in North Carolina. In addition, she holds patents licensed to Chymia LLC and PsyProtix with royalties and ownership. M.A. and G.K. are co-inventors (through their institutions) on patents on applications of metabolomics in diseases of the central nervous system. M.A. and G.K. hold equity in Chymia LLC and IP in PsyProtix and Atai which is unrelated to this work). P.M.D. has received research grants from the National Institute on Aging, DARPA, DOD, ONR, Salix, Avanir, Avid, Cure Alzheimer’s Fund, Karen L. Wrenn Trust, Steve Aoki Foundation, and advisory/board fees from Apollo, Brain Forum, Clearview, Lumos, Neuroglee, Otsuka, Verily, Vitakey, Sermo, Lilly, Nutricia, Alzheon, and Transposon. P.M.D. is a co-inventor on patents for the diagnosis or treatment of dementia. P.M.D. owns shares/options in Evidation, Marvel Biome, UMethod, Transposon, and Alzheon. A.J.S. has received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); NIH NHLBI (MESA Observational Study Monitoring Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). The remaining authors declare no competing interests.